Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)

Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study incl...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Zettl, Uwe K. [verfasserIn] Henze, Thomas Essner, Ute Flachenecker, Peter

Format:	Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	Multiple sclerosis Spasticity Quality of life Burden of disease Cost

Anmerkung:	© Springer-Verlag Berlin Heidelberg 2013

Übergeordnetes Werk:	Enthalten in: The European journal of health economics - Springer Berlin Heidelberg, 2001, 15(2013), 9 vom: 01. Dez., Seite 953-966
Übergeordnetes Werk:	volume:15 ; year:2013 ; number:9 ; day:01 ; month:12 ; pages:953-966

Links:	Volltext

DOI / URN:	10.1007/s10198-013-0537-5

Katalog-ID:	OLC2052294783

Internformat


LEADER	01000caa a22002652 4500
001	OLC2052294783
003	DE-627
005	20230510123544.0
007	tu
008	200820s2013 xx \|\|\|\|\| 00\| \|\|eng c
024	7		\|a 10.1007/s10198-013-0537-5 \|2 doi
035			\|a (DE-627)OLC2052294783
035			\|a (DE-He213)s10198-013-0537-5-p
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 330 \|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.05$jGesundheitsökonomie \|2 bkl
084			\|a 44.10$jGesundheitswesen: Allgemeines \|2 bkl
100	1		\|a Zettl, Uwe K. \|e verfasserin \|4 aut
245	1	0	\|a Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a ohne Hilfsmittel zu benutzen \|b n \|2 rdamedia
338			\|a Band \|b nc \|2 rdacarrier
500			\|a © Springer-Verlag Berlin Heidelberg 2013
520			\|a Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity.
650		4	\|a Multiple sclerosis
650		4	\|a Spasticity
650		4	\|a Quality of life
650		4	\|a Burden of disease
650		4	\|a Cost
700	1		\|a Henze, Thomas \|4 aut
700	1		\|a Essner, Ute \|4 aut
700	1		\|a Flachenecker, Peter \|4 aut
773	0	8	\|i Enthalten in \|t The European journal of health economics \|d Springer Berlin Heidelberg, 2001 \|g 15(2013), 9 vom: 01. Dez., Seite 953-966 \|w (DE-627)328188557 \|w (DE-600)2045253-6 \|w (DE-576)09442246X \|x 1618-7598 \|7 nnns
773	1	8	\|g volume:15 \|g year:2013 \|g number:9 \|g day:01 \|g month:12 \|g pages:953-966
856	4	1	\|u https://doi.org/10.1007/s10198-013-0537-5 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a SSG-OLC-WIW
912			\|a SSG-OLC-PHA
912			\|a SSG-OLC-DE-84
912			\|a GBV_ILN_26
912			\|a GBV_ILN_267
912			\|a GBV_ILN_287
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_4219
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4310
912			\|a GBV_ILN_4314
936	b	k	\|a 44.05$jGesundheitsökonomie \|q VZ \|0 106409611 \|0 (DE-625)106409611
936	b	k	\|a 44.10$jGesundheitswesen: Allgemeines \|q VZ \|0 106409530 \|0 (DE-625)106409530
951			\|a AR
952			\|d 15 \|j 2013 \|e 9 \|b 01 \|c 12 \|h 953-966

Indexfelder

author_variant	u k z uk ukz t h th u e ue p f pf
matchkey_str	article:16187598:2013----::udnfiesimlilslrssainsihpsiiynemnmb
hierarchy_sort_str	2013
bklnumber	44.05$jGesundheitsökonomie 44.10$jGesundheitswesen: Allgemeines
publishDate	2013
allfields	10.1007/s10198-013-0537-5 doi (DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Zettl, Uwe K. verfasserin aut Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) 2013 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2013 Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. Multiple sclerosis Spasticity Quality of life Burden of disease Cost Henze, Thomas aut Essner, Ute aut Flachenecker, Peter aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 15(2013), 9 vom: 01. Dez., Seite 953-966 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:15 year:2013 number:9 day:01 month:12 pages:953-966 https://doi.org/10.1007/s10198-013-0537-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 15 2013 9 01 12 953-966
spelling	10.1007/s10198-013-0537-5 doi (DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Zettl, Uwe K. verfasserin aut Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) 2013 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2013 Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. Multiple sclerosis Spasticity Quality of life Burden of disease Cost Henze, Thomas aut Essner, Ute aut Flachenecker, Peter aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 15(2013), 9 vom: 01. Dez., Seite 953-966 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:15 year:2013 number:9 day:01 month:12 pages:953-966 https://doi.org/10.1007/s10198-013-0537-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 15 2013 9 01 12 953-966
allfields_unstemmed	10.1007/s10198-013-0537-5 doi (DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Zettl, Uwe K. verfasserin aut Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) 2013 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2013 Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. Multiple sclerosis Spasticity Quality of life Burden of disease Cost Henze, Thomas aut Essner, Ute aut Flachenecker, Peter aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 15(2013), 9 vom: 01. Dez., Seite 953-966 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:15 year:2013 number:9 day:01 month:12 pages:953-966 https://doi.org/10.1007/s10198-013-0537-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 15 2013 9 01 12 953-966
allfieldsGer	10.1007/s10198-013-0537-5 doi (DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Zettl, Uwe K. verfasserin aut Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) 2013 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2013 Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. Multiple sclerosis Spasticity Quality of life Burden of disease Cost Henze, Thomas aut Essner, Ute aut Flachenecker, Peter aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 15(2013), 9 vom: 01. Dez., Seite 953-966 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:15 year:2013 number:9 day:01 month:12 pages:953-966 https://doi.org/10.1007/s10198-013-0537-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 15 2013 9 01 12 953-966
allfieldsSound	10.1007/s10198-013-0537-5 doi (DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Zettl, Uwe K. verfasserin aut Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) 2013 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2013 Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. Multiple sclerosis Spasticity Quality of life Burden of disease Cost Henze, Thomas aut Essner, Ute aut Flachenecker, Peter aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 15(2013), 9 vom: 01. Dez., Seite 953-966 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:15 year:2013 number:9 day:01 month:12 pages:953-966 https://doi.org/10.1007/s10198-013-0537-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 15 2013 9 01 12 953-966
language	English
source	Enthalten in The European journal of health economics 15(2013), 9 vom: 01. Dez., Seite 953-966 volume:15 year:2013 number:9 day:01 month:12 pages:953-966
sourceStr	Enthalten in The European journal of health economics 15(2013), 9 vom: 01. Dez., Seite 953-966 volume:15 year:2013 number:9 day:01 month:12 pages:953-966
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Multiple sclerosis Spasticity Quality of life Burden of disease Cost
dewey-raw	330
isfreeaccess_bool	false
container_title	The European journal of health economics
authorswithroles_txt_mv	Zettl, Uwe K. @@aut@@ Henze, Thomas @@aut@@ Essner, Ute @@aut@@ Flachenecker, Peter @@aut@@
publishDateDaySort_date	2013-12-01T00:00:00Z
hierarchy_top_id	328188557
dewey-sort	3330
id	OLC2052294783
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2052294783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510123544.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2013 xx \|\|\|\|\| 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10198-013-0537-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2052294783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s10198-013-0537-5-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zettl, Uwe K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag Berlin Heidelberg 2013</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Spasticity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Quality of life</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Burden of disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henze, Thomas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Essner, Ute</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flachenecker, Peter</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The European journal of health economics</subfield><subfield code="d">Springer Berlin Heidelberg, 2001</subfield><subfield code="g">15(2013), 9 vom: 01. Dez., Seite 953-966</subfield><subfield code="w">(DE-627)328188557</subfield><subfield code="w">(DE-600)2045253-6</subfield><subfield code="w">(DE-576)09442246X</subfield><subfield code="x">1618-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:9</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:953-966</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s10198-013-0537-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-WIW</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_287</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="q">VZ</subfield><subfield code="0">106409611</subfield><subfield code="0">(DE-625)106409611</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="q">VZ</subfield><subfield code="0">106409530</subfield><subfield code="0">(DE-625)106409530</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">9</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield><subfield code="h">953-966</subfield></datafield></record></collection>
author	Zettl, Uwe K.
spellingShingle	Zettl, Uwe K. ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Multiple sclerosis misc Spasticity misc Quality of life misc Burden of disease misc Cost Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
authorStr	Zettl, Uwe K.
ppnlink_with_tag_str_mv	@@773@@(DE-627)328188557
format	Article
dewey-ones	330 - Economics 610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut
collection	OLC
remote_str	false
illustrated	Not Illustrated
issn	1618-7598
topic_title	330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) Multiple sclerosis Spasticity Quality of life Burden of disease Cost
topic	ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Multiple sclerosis misc Spasticity misc Quality of life misc Burden of disease misc Cost
topic_unstemmed	ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Multiple sclerosis misc Spasticity misc Quality of life misc Burden of disease misc Cost
topic_browse	ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Multiple sclerosis misc Spasticity misc Quality of life misc Burden of disease misc Cost
format_facet	Aufsätze Gedruckte Aufsätze
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	nc
hierarchy_parent_title	The European journal of health economics
hierarchy_parent_id	328188557
dewey-tens	330 - Economics 610 - Medicine & health
hierarchy_top_title	The European journal of health economics
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X
title	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
ctrlnum	(DE-627)OLC2052294783 (DE-He213)s10198-013-0537-5-p
title_full	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
author_sort	Zettl, Uwe K.
journal	The European journal of health economics
journalStr	The European journal of health economics
lang_code	eng
isOA_bool	false
dewey-hundreds	300 - Social sciences 600 - Technology
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	953
author_browse	Zettl, Uwe K. Henze, Thomas Essner, Ute Flachenecker, Peter
container_volume	15
class	330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl
format_se	Aufsätze
author-letter	Zettl, Uwe K.
doi_str_mv	10.1007/s10198-013-0537-5
normlink	106409611 106409530
normlink_prefix_str_mv	106409611 (DE-625)106409611 106409530 (DE-625)106409530
dewey-full	330 610
title_sort	burden of disease in multiple sclerosis patients with spasticity in germany: mobility improvement study (move i)
title_auth	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
abstract	Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. © Springer-Verlag Berlin Heidelberg 2013
abstractGer	Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. © Springer-Verlag Berlin Heidelberg 2013
abstract_unstemmed	Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. © Springer-Verlag Berlin Heidelberg 2013
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_26 GBV_ILN_267 GBV_ILN_287 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314
container_issue	9
title_short	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
url	https://doi.org/10.1007/s10198-013-0537-5
remote_bool	false
author2	Henze, Thomas Essner, Ute Flachenecker, Peter
author2Str	Henze, Thomas Essner, Ute Flachenecker, Peter
ppnlink	328188557
mediatype_str_mv	n
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s10198-013-0537-5
up_date	2024-07-03T14:32:46.693Z
_version_	1803568720586473472
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2052294783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510123544.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2013 xx \|\|\|\|\| 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10198-013-0537-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2052294783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s10198-013-0537-5-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zettl, Uwe K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag Berlin Heidelberg 2013</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To describe the current management patterns of multiple sclerosis (MS) patients with spasticity in Germany and the impact of MS spasticity on quality of life (QoL) and associated costs. Methods Non-interventional, multicentre, cross-sectional and retrospective burden-of-disease study including 414 MS patients with spasticity (age from 25 to 80 years) from 42 clinical practices across Germany. All patients were diagnosed with MS-related spasticity based on neurological examination at least 12 months before inclusion in the study. Three different forms were completed on different aspects of the disease: the patient questionnaire, the chart documentation form and the physician questionnaire. Results Mild, moderate and severe spasticity were found in 27.3, 44.0 and 28.7 % of patients, respectively. Associated symptoms and QoL scores were worse in patients with higher degrees of spasticity. In particular, higher mean scores for sleep impairment (mild vs. severe, 2.1 vs. 4.3), mean spasm count (3/day vs. 10.1/day), mean WEIMuS fatigue score (15.8 vs. 19.8), increased walking time (9.6 vs. 20.2 s) and lower mean QoL scores (MSQoL-54 physical subscale, 54.9 vs. 39.5; EQ-5D, 0.60 vs. 0.30) were reported in patients with severe spasticity in comparison to patients with mild spasticity. Patient management mainly comprised physiotherapy (mild vs. severe, 65.5 vs. 85.7 %) and medication (84.2 vs. 64.8 %) with baclofen. The average cost for patients with mild spasticity was €2,268/year, increasing to €8,688/patient/year for patients with severe spasticity. The health insurance costs showed the same trend. Conclusions MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Spasticity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Quality of life</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Burden of disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henze, Thomas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Essner, Ute</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flachenecker, Peter</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The European journal of health economics</subfield><subfield code="d">Springer Berlin Heidelberg, 2001</subfield><subfield code="g">15(2013), 9 vom: 01. Dez., Seite 953-966</subfield><subfield code="w">(DE-627)328188557</subfield><subfield code="w">(DE-600)2045253-6</subfield><subfield code="w">(DE-576)09442246X</subfield><subfield code="x">1618-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:9</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:953-966</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s10198-013-0537-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-WIW</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_287</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="q">VZ</subfield><subfield code="0">106409611</subfield><subfield code="0">(DE-625)106409611</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="q">VZ</subfield><subfield code="0">106409530</subfield><subfield code="0">(DE-625)106409530</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">9</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield><subfield code="h">953-966</subfield></datafield></record></collection>
score	7.403063

Nicht das Richtige dabei?

Schreiben Sie uns!

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?